Oseltamivir News and Research

RSS

Current recommendations advise prompt antiviral treatment for high-risk patients with influenza

Patients likely to benefit the most from antiviral therapy for influenza were prescribed these drugs infrequently during the 2012-2013 influenza season, while antibiotics may have been overprescribed.

17 Jul 2014

Janssen signs license agreement with Vertex to develop, commercialize VX-787 for influenza A treatment

Janssen Pharmaceuticals, Inc.announced today that it has entered into an exclusive license agreement with Vertex Pharmaceuticals for the worldwide development, manufacturing and commercialization of VX-787, a novel medicine in Phase II development for the treatment of influenza A.

18 Jun 2014

Guidance on use of Tamiflu needs to be reviewed in light of most recent evidence

Tamiflu (the antiviral drug oseltamivir) shortens symptoms of influenza by half a day, but there is no good evidence to support claims that it reduces admissions to hospital or complications of influenza.

11 Apr 2014

Scientists map key elements of immune overreaction triggered by influenza virus infection

Scientists at The Scripps Research Institute (TSRI) have mapped key elements of a severe immune overreaction—a "cytokine storm"—that can both sicken and kill patients who are infected with certain strains of flu virus.

3 Mar 2014

TSRI scientists describe severe immune overreaction caused by flu infections

Scientists at The Scripps Research Institute have mapped key elements of a severe immune overreaction—a “cytokine storm”—that can both sicken and kill patients who are infected with certain strains of flu virus.

28 Feb 2014

Scientists identify factors that predict flu severity in patients

St. Jude Children's Research Hospital scientists have identified a signature immune response that might help doctors identify which newly diagnosed influenza patients are most likely to develop severe symptoms and suffer poor outcomes. The findings also help explain why infants and toddlers are at elevated risk for flu complications. The research appears in the upcoming issue of the American Journal of Respiratory and Critical Care Medicine.

10 Feb 2014

New drug-resistant strain of bird flu appears to retain ability to cause serious disease in humans

Researchers at the Icahn School of Medicine at Mount Sinai reported that a virulent new strain of influenza - the virus that causes the flu - appears to retain its ability to cause serious disease in humans even after it develops resistance to antiviral medications. The finding was included in a study that was published today in the journal Nature Communications.

12 Dec 2013

Pediatrician analyzes management of the 2009 influenza A crisis

With autumn just around the corner and a new flu strain lying in wait for us, the presentation of a study analysing the management of the 2009 influenza A crisis could not, if anything, be better timed.

26 Nov 2013

Taiwan scientists confirm world’s first case of wild avian influenza A H6N1 virus in human

Scientists from Taiwan report on the world’s first confirmed case of human infection with a wild avian influenza A H6N1 virus in The Lancet Respiratory Medicine.

14 Nov 2013

NanoViricides, LRRI sign NDA for IND-enabling efficacy studies on FluCide drug candidates

NanoViricides, Inc. said it has signed a non-disclosure agreement with the Lovelace Respiratory Research Institute. The Company intends to enter into a Master Services Agreement with LRRI for the IND-enabling efficacy studies of both its broad-spectrum injectable and oral FluCide drug candidates.

5 Aug 2013

Some strains of avian H7N9 influenza develop resistance to antiviral drugs

Some strains of the avian H7N9 influenza that emerged in China this year have developed resistance to the only antiviral drugs available to treat the infection, but testing for antiviral resistance can give misleading results, helping hasten the spread of resistant strains.

17 Jul 2013

Romark Laboratories starts NT-300 Phase 3 trial for treatment of acute uncomplicated influenza

Romark Laboratories announced that it has begun enrolling patients in a global Phase 3 clinical trial of NT-300 (nitazoxanide) for treatment of acute uncomplicated influenza.

19 Apr 2013

New assays are effective in managing patients with influenza virus infection

Over 40,000 people die each year in the United States from influenza-related diseases. In patients whose immune systems are compromised, antiviral therapy may be life-saving, but it needs to be initiated quickly. It is therefore crucial to diagnose and type the influenza rapidly.

18 Apr 2013

Study: Half of Tamiflu prescriptions during 2009-10 influenza pandemic went unused in England

A new study concludes that approximately half of the prescriptions of Tamiflu during the 2009-10 influenza pandemic went unused in England.

18 Apr 2013

Genetic analysis of H7N9 portrays that virus evolves to adapt to human cells

A genetic analysis of the avian flu virus responsible for at least nine human deaths in China portrays a virus evolving to adapt to human cells, raising concern about its potential to spark a new global flu pandemic.

15 Apr 2013

LASAG trial for severe influenza initiated

...

12 Feb 2013

Three NIH-sponsored influenza trials begin to enroll volunteers

Three clinical trials that seek to find more effective treatments for influenza are enrolling volunteers with influenza at the National Institutes of Health's Clinical Center in Bethesda, Md., and at several dozen other domestic and international sites.

6 Feb 2013

NanoViricides’ oral FluCide dramatically improves survival in animals with H3N2 influenza A

NanoViricides, Inc. reported today that its oral FluCide drug candidates demonstrated dramatically improved survival in animals administered a lethal dose of the H3N2 influenza A virus.

24 Sep 2012

Strong antiviral antibody response observed in oral administration of Flucide

NanoViricides, Inc. announced today that anti-influenza drug candidates under its FluCide program, when given orally, led to strong antiviral antibody response. The antibody response with Oral administration was stronger than that with IV administration and was substantially greater than that observed with oseltamivir.

5 Sep 2012

Oral FluCide drug candidates effective in reducing lung viral load: NanoViricides

NanoViricides, Inc. announced today that anti-influenza drug candidates under its FluCide program, when given orally, were nearly as effective as when administered as IV injections in terms of reduction in lung viral load.

27 Aug 2012